Standard Life Aberdeen plc Has $7.71 Million Position in Mylan (MYL)
Standard Life Aberdeen plc boosted its position in shares of Mylan (NASDAQ:MYL) by 20.4% during the 4th quarter, Holdings Channel reports. The firm owned 182,046 shares of the company’s stock after acquiring an additional 30,851 shares during the quarter. Standard Life Aberdeen plc’s holdings in Mylan were worth $7,708,000 at the end of the most recent quarter.
A number of other large investors have also recently modified their holdings of MYL. Pzena Investment Management LLC grew its stake in Mylan by 84.1% in the 3rd quarter. Pzena Investment Management LLC now owns 22,721,384 shares of the company’s stock worth $712,770,000 after acquiring an additional 10,381,697 shares in the last quarter. Greenlight Capital Inc. grew its stake in Mylan by 0.4% in the 3rd quarter. Greenlight Capital Inc. now owns 10,744,307 shares of the company’s stock worth $337,048,000 after acquiring an additional 42,600 shares in the last quarter. Bank of New York Mellon Corp grew its stake in Mylan by 30.3% in the 4th quarter. Bank of New York Mellon Corp now owns 5,334,789 shares of the company’s stock worth $225,715,000 after acquiring an additional 1,239,089 shares in the last quarter. Orbimed Advisors LLC grew its stake in Mylan by 20.9% in the 3rd quarter. Orbimed Advisors LLC now owns 3,601,100 shares of the company’s stock worth $112,967,000 after acquiring an additional 621,900 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in Mylan by 20.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 3,553,480 shares of the company’s stock worth $111,450,000 after acquiring an additional 612,513 shares in the last quarter. Institutional investors own 76.86% of the company’s stock.
In related news, CEO Heather M. Bresch sold 75,000 shares of the stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $45.00, for a total transaction of $3,375,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.69% of the company’s stock.
Mylan (NASDAQ:MYL) last posted its earnings results on Wednesday, February 28th. The company reported $1.43 EPS for the quarter, beating the Zacks’ consensus estimate of $1.41 by $0.02. Mylan had a net margin of 5.84% and a return on equity of 19.14%. The company had revenue of $3.24 billion during the quarter, compared to analysts’ expectations of $3.29 billion. During the same quarter in the prior year, the company posted $1.57 earnings per share. Mylan’s revenue for the quarter was down .9% compared to the same quarter last year. equities analysts forecast that Mylan will post 5.39 EPS for the current fiscal year.
A number of equities analysts have commented on the stock. Goldman Sachs Group upped their target price on shares of Mylan from $46.00 to $52.00 and gave the stock a “buy” rating in a research note on Thursday, January 11th. ValuEngine downgraded shares of Mylan from a “buy” rating to a “hold” rating in a research note on Friday. Royal Bank of Canada upped their target price on shares of Mylan from $32.00 to $37.00 and gave the stock a “sector perform” rating in a research note on Tuesday, November 7th. Citigroup restated a “buy” rating and issued a $58.00 target price (up from $48.00) on shares of Mylan in a research note on Thursday, January 4th. Finally, Leerink Swann assumed coverage on shares of Mylan in a research note on Tuesday, January 2nd. They issued a “market perform” rating and a $44.00 target price on the stock. Ten research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $45.37.
Mylan Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan (NASDAQ:MYL).
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.